Interleukin-21 Drives a Hypermetabolic State and CD4⁺ T Cell-associated Pathogenicity in Chronic Intestinal Inflammation

Abstract

BACKGROUND & AIMS:

Incapacitated regulatory T cells (Tregs) contribute to immune-mediated diseases. Inflammatory Tregs are evident during human inflammatory bowel disease (IBD); however, mechanisms driving the development of these cells and their function are not well understood. Therefore, we investigated the role of cellular metabolism in Tregs relevant to gut homeostasis.

METHODS:

Using human Tregs, we performed mitochondrial ultrastructural studies via electron microscopy and confocal imaging, biochemical and protein analyses using proximity ligation assay, immunoblotting, mass cytometry and fluorescence-activated cell sorting, metabolomics, gene expression analysis, and real-time metabolic profiling utilizing Seahorse XF analyzer. We utilized Crohn’s disease single-cell RNA sequencing dataset to infer therapeutic relevance of targeting metabolic pathways in inflammatory Tregs. We examined the superior functionality of genetically-modified Tregs in CD4⁺ T cell-induced murine colitis models.

RESULTS:

Mitochondria-endoplasmic reticulum (ER) appositions, known to mediate pyruvate entry into mitochondria via VDAC1, are abundant in Tregs. VDAC1 inhibition perturbed pyruvate metabolism, eliciting sensitization to other inflammatory signals reversible by membrane-permeable methyl pyruvate (MePyr) supplementation. Notably, IL-21 diminished mitochondria-ER appositions, resulting in enhanced enzymatic function of glycogen synthase kinase 3 β (GSK3β), a putative negative regulator of VDAC1, and a hypermetabolic state that amplified Treg inflammatory response. MePyr and GSK3β pharmacologic inhibitor (LY2090314) reversed IL-21-induced metabolic rewiring and inflammatory state. Moreover, IL-21-induced metabolic genes in Tregs in vitro were enriched in human Crohn’s disease intestinal Tregs. Adoptively transferred Il21r^−/− Tregs efficiently rescued murine colitis in contrast to wild-type Tregs.

CONCLUSIONS:

IL-21 triggers metabolic dysfunction associated with Treg inflammatory response. Inhibiting IL-21-induced metabolism in Tregs may mitigate CD4⁺ T cell-driven chronic intestinal inflammation.

Graphical Abstract

Introduction

Persistent activation of diverse cytokine pathways in adaptive immune cells, such as CD4⁺ T cell subsets, is a hallmark of immune-mediated diseases, including human inflammatory bowel disease (IBD)¹. IBD, mainly Crohn’s disease (CD) and ulcerative colitis (UC), is a relapsing disorder characterized by gastrointestinal tissue damage and extraintestinal manifestations, with a high rate of surgical interventions². Despite the therapeutic success of biologics against T cells, such as anti-tumor necrosis factor α (TNF-α), anti-p40 subunit shared by interleukin-12 (IL-12) and IL-23, and anti-integrin, inconsistent patient response remains a clinical concern³. Thus, our understanding of IBD is incomplete, highlighting the need to investigate critical drivers of inflammatory CD4⁺ T cells to uncover resistance mechanisms and maximize responsiveness.

Upon antigen-induced activation, naïve CD4⁺ T cells consume glucose, proliferate, and differentiate into functionally distinct regulatory and effector T helper (Th) cell lineages, as evidenced by unique transcription factor expression, metabolic programs, and cytokine expression⁴. In regulatory T cells (Tregs), transforming growth factor-beta 1 (TGF-β1) sustains the expression of Treg-defining forkhead domain-containing protein 3 (FOXP3) transcription factor necessary to subdue effector T cell-driven diseases^{5, 6}. Indeed, patients and mice lacking functional TGF-β1 develop multiorgan inflammation including IBD^{7, 8}.

The recent discovery of the interface between the immune system and metabolism is contributing immensely to our understanding of the complexity of immune cell regulation. Metabolic pathways differentially govern T cell differentiation and immune response, such as intracellular cytokine production and cell trafficking⁹. For instance, activated CD4⁺ T cells favor glycolysis (conversion of glucose-derived pyruvate to lactate) and glutaminolysis, with decreased entry of pyruvate into mitochondria^{10, 11}. Pyruvate lies at the intersection between glycolysis and mitochondrial tricarboxylic acid (TCA) cycle, where immunometabolic hubs controlled by mitochondria-associated membranes (MAMs) are present¹². However, how micro-environmental cues control pyruvate metabolism in human Tregs is unclear. Metabolites not only promote the activity of the electron transport chain (ETC) but also enhance the generation of mitochondrial reactive oxygen species (mtROS) and mitochondrial DNA linked to signaling events and cellular function¹³. While several metabolic pathways, including glycolysis, underlie effector CD4⁺ T cell-mediated pathologies¹⁴, it is unresolved whether metabolic dysfunction is associated with Treg abnormality reported during human IBD pathogenesis^15–18. Extracellular cues, such as TGF-β1, IL-6, IL-12, IL-21, and IL-23, are known to control the balance between Treg and effector T cell response^{1, 19}. Yet how Tregs sense extracellular cues and integrate signals by fine-tuning MAMs to reshape extra- and intra-cellular metabolites, intracellular cytokines, cell migration, and immune response in healthy and inflammatory conditions are poorly understood. Thus, we explored the possible role of MAMs, such as those enriched with the endoplasmic reticulum (ER), in responding to cues that control metabolic signaling events relevant to Treg immune-suppressive function.

Here, we showed that inhibition of pyruvate transport at mitochondria-associated ER membranes or the inner mitochondrial membrane (IMM) in induced Tregs (iTregs) triggered metabolic changes that resulted in sensitization to the acquisition of an effector T cell phenotype. Moreover, we identified IL-21 as the cytokine that uncoupled mitochondria from ER, resulting in enhanced glycogen synthase kinase 3 β (GSK3β) function, metabolic rewiring including glycolysis, pyruvate accumulation and exacerbation of IL-12-induced inflammatory response. Like GSK3β pharmacologic inhibition, supplementation of iTregs with mitochondria membrane-permeable methyl pyruvate impaired glycolysis and inflammatory response triggered by IL-21 and IL-12. Overall, IL-21 exploited GSK3β, a metabolic checkpoint, to promote intracellular rewiring of iTregs. Notably, we found that IL-21-induced metabolic genes in iTregs were significantly enriched in intestinal Tregs of refractory IBD patients. In naïve CD4⁺ T cell-induced murine colitis, IL-21 receptor (IL-21R)-deficient Tregs were more efficient in alleviating disease severity than wild-type Tregs.

Materials and Methods

Please see Supplementary Materials and Methods Section.

Results

Mitochondria-ER Appositions are Present in Human Tregs

Mitochondria and ER membranes can serve as immunometabolic hubs involved in facilitating pyruvate metabolism and mitochondrial respiration^{20, 21}. At mitochondria-ER junctions, voltage-dependent anion channel 1 (VDAC1) on the outer mitochondrial membrane (OMM) and inositol triphosphate receptor 1 (IP3R1) on the ER tethers mitochondria and ER membranes to facilitate mitochondrial influx of pyruvate^{12, 22, 23}. Yet limited data exist about how mitochondria-ER actively transform its ultrastructure to regulate Treg immune response. We therefore performed fundamental characterization of human Tregs to identify mitochondrial-ER appositions.

Induced Tregs (iTregs), well established to function in vitro and in vivo²⁴, were derived from naïve CD4⁺ T cells isolated from healthy human peripheral blood mononuclear cell (PBMC) donors (Figure 1A). Human iTregs and naïve control cells were subjected to transmission electron microscopy (TEM) to visualize mitochondria. Electron microscopy images showed that iTregs displayed a higher percentage of mitochondria in close association with ER than naïve cells where these interactions were minimal (59.04% vs. 3.27%, P < 0.0001, Figure 1B, C). Thus, electron-dense zones between the OMM and ER at contact sites in iTregs indicated that these were distinct subcellular structures (Figure 1B bottom panels – black arrows). TEM also revealed disparities in mitochondrial morphology. Human iTregs displayed long, tubular mitochondria associated with mitochondrial respiration²⁵, while mitochondria in naïve cells were rounded (mitochondrial aspect ratio per cell: 3.11 vs. 1.67, P < 0.0001, and aspect ratio per mitochondrion: 3.25 vs. 1.68, P < 0.0001, Supplementary Figure 1A–C). We substantiated our EM ultrastructural assessment with fluorescent-based organelle tracking in live cells. Imaging data showed higher mitochondria-ER co-localization in iTregs than in naïve cells (Pearson’s coefficient of 0.58 vs. 0.39, P < 0.001, and 0.56 vs. 0.44, P < 0.01, using two different MitoTracker dyes, Supplementary Figure 1D, E). Fixed iTregs and CD4⁺ CD25⁺ CD127^dim/− T cells (human natural Tregs) were stained with VDAC1 and IP3R1 monoclonal antibodies, then subjected to proximity ligation assay (PLA) to biochemically quantify mitochondria-ER interactions. PLA can reliably detect protein-protein interactions of ≤ 30 nm distance in situ with high specificity and sensitivity. The discrete red PLA signals suggested that mitochondria-ER appositions were present in iTregs (Figure 1D, E) and natural Tregs (Supplementary Figure 1F).

Figure 1. Mitochondria-ER Appositions are Present in Human Tregs.

(A) Experimental workflow for naïve CD4⁺ T cell isolation from PBMCs and differentiation into iTregs.

(B and C) Transmission electron microscopy (TEM) images of naïve cells (top panels) vs. iTregs (bottom panels) with enlarged images of mitochondria (mito)-ER contact. Black arrows indicate electron-dense regions; scale bars, 2 μm (B). Graph shows mitochondria in contact with ER per cell in TEM images; naïve cells (n = 51) and iTregs (n = 29) (C).

(D) Representative images show mito-ER contact in red after PLA, cell structure in differential interference contrast (DIC), and nucleus stained with 4’,6’-diamidino-2-phenylinode (DAPI) (DNA, blue); scale bar, 2 μm. Graph shows the number of PLA signals (mito-ER contact) per cell (n = 239 iTregs, n = 90 naïve cells).

(E) Graphical summary of mitochondria-ER interaction detected via VDAC1-IP3R1 binding in human Tregs.

(F) Experimental workflow for lamina propria (LP) CD4⁺ T cell isolation and PLA.

(G) Representative images show mito-ER contact in red, DAPI in LP CD4⁺ T cells in the presence (bottom panels) or absence (top panels) of (±) TGF-β1 (25 ng/ml) stimulation; scale bar, 2 μm.

(H) Graph shows quantitation of mito-ER contact (PLA signals) per LP CD4⁺ T cell; vehicle-stimulated cells (n = 17) and TGF-β1-stimulated cells (n = 18).

Data represents mean ± SEM from 2–3 independent experiments or biological replicates. **** p < 0.0001, using two-tailed Student’s t-test.

Healthy lamina propria (LP) CD4⁺ T cells known to exhibit Treg-like phenotype and respond to TGF-β1^{26, 27} were isolated from human intestinal biopsies and examined for mitochondria-ER interaction via PLA (Figure 1F). We found mitochondria-ER interactions in a subset of LP CD4⁺ T cells (Figure 1G top panels), and these interactions were enhanced by TGF-β1 (4 vs. 11 PLA signals per cell, P < 0.0001, Figure 1G, H). IP3R1 interaction was specific to VDAC1 in contrast to translocase of the outer mitochondrial membrane 20 (TOM20) where TOM20-IP3R1 binding was minimal (98% vs. 5% PLA⁺ LP CD4⁺ T cells, P < 0.0001, Supplementary Figure 1G), which supports the specificity of this interaction. Using complementary approaches in human samples, mitochondria-ER interactions – detected via VDAC1-IP3R1 binding – are present in human Tregs.

VDAC1 Inhibition Alters iTreg Metabolic State and Sensitizes to IL-12-induced Inflammatory Response

Previous study has demonstrated the capacity to generate functional iTregs in the absence of TGF-β1²⁸. We showed VDAC1-IP3R1 interactions, i.e., mitochondria-ER appositions, were more abundant in iTregs generated in the presence of TGF-β1 than iTregs derived in the absence of TGF-β1 on day 5 (P < 0.001) and 7 (P < 0.001) as shown Figure 2A–C. As controls, we showed successful development of FOXP3⁺ cells in both cell types (Supplementary Figure 2A), while TGF-β1-induced CD103 (αE) integrin²⁹ confirmed cellular responsiveness to TGF-β1 (Supplementary Figure 2B). Mitochondria-ER interaction has been linked to mitochondrial pyruvate transport and oxidative phosphorylation (OXPHOS)^{12, 20}. Consistent with these reports, oxygen consumption rate (OCR) was higher in iTregs generated in the presence of TGF-β1 than iTregs derived in the absence of TGF-β1, as evidenced by increased basal, ATP-coupled, and FCCP-induced OCR (Figure 2D). In summary, abundant mitochondria-ER interactions correlate with higher OCR, which we found to be less enriched in effector Th1, Th2, and Th17 cells (Figure 2E and Supplementary Figure 2C). We then explored whether perturbing mitochondria-ER function, i.e., pyruvate transport, would impact OCR and Treg immune response.

Figure 2. VDAC1 Inhibition Alters iTreg Metabolic State and Sensitizes to IL-12-induced Inflammatory Response.

(A) Experimental workflow for the generation of human iTregs in the absence or presence of TGF-β1.

(B and C) Representative PLA images of iTregs ± TGF-β1 show mito-ER contacts in red on day 5 (B) or in white on day 7 (C); scale bars, 2 μm and 10 μm. Graphs show PLA⁺ cells on day 5 (n = 257 vs. n = 200) (B) and on day 7 (n = 129 vs. n = 119) (C).

(D) Representative oxygen consumption rate (OCR) profile of iTreg cell types before and after mitochondrial perturbation (n = 3). Bar graphs show calculated basal respiration, ATP production, maximal respiration, and spare respiratory capacity; mean ± SEM from 10–12 technical replicates.

(E) Representative PLA images show mito-ER contact in iTregs vs. effector T helper cells (n = 3 biological donors); scale bar, 10 μm.

(F) Representative OCR profile of iTregs ± clotrimazole (clot), bifonazole (bifo) or UK5099 (n = 3). Bar graphs show calculated basal respiration, ATP production, maximal respiration, and spare respiratory capacity; mean ± SEM from 12 technical replicates.

(G) Relative mRNA expression in transfected iTregs via RT-qPCR (n = 3).

(H) Percentage of TNF-α⁺ in iTregs, as determined by flow cytometry (n = 3–4).

Data represents mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001, using two-tailed Student’s t-test or one-way ANOVA followed by Bonferroni test for multiple comparisons.

At the OMM, mitochondria-ER interactions stabilize hexokinase (HK)-I localization, thereby activating VDAC1 and directing pyruvate into the IMM via the mitochondrial pyruvate carrier (MPC)^{12, 30, 31}. Thus, we reasoned that VDAC1 inhibition in iTregs would diminish pyruvate transport and OCR. Consistent with our hypothesis, acute inhibition (2 h) of HK-I-mediated activation of VDAC1 with clotrimazole or bifonazole³², herein referred to as clot and bifo (10–20 μM), reduced OCR (basal OCR, ATP-linked OCR, FCCP-induced maximal OCR, space respiratory capacity: P < 0.0001, Figure 2F). Similarly, UK5099 (2–20 μM, 2 h)-mediated destabilization of MPC protein complexes decreased OCR (ATP-linked OCR: P < 0.05, FCCP-induced maximal OCR: P < 0.0001, spare respiratory capacity: P < 0.0001) Supplementary Figure 2D). Of note, siRNA-mediated depletion of VDAC1 increased the mRNA expression of TNF (P < 0.05) and glycolysis genes, such as glucose transporter 3 (GLUT3; SLC2A3, P < 0.0001) and pyruvate kinase M 2 (PKM2, P < 0.05) (Figure 2G). In agreement with VDAC1 depletion, clotrimazole treatment sensitized cells to IL-12, a known activator of signal transducer and activator of transcription 4 (STAT4) and Th1 signature TNF-α and IFN-γ cytokines, as evidenced by increased percentage of TNF-α⁺ iTregs (Figure 2H left). Mechanistically tying this inflammatory response to impaired mitochondrial pyruvate transport, supplementation with methyl pyruvate (MePyr, 10 mM), a mitochondria membrane-permeable metabolite (Figure 2H right), reversed clotrimazole-mediated TNF-α production. Like the VDAC1 inhibitor, UK5099 increased the percentage of IL-12-induced IFN-γ⁺ iTregs, with IFN-γ⁺ iTregs enriched in T cell homing CD49D (α4) integrin (Supplementary Figure 2E). By utilizing various approaches, we inferred that interfering with pyruvate transport at the OMM or IMM induced metabolic rewiring that sensitized iTregs to acquiring an effector T cell-like phenotype (Supplementary Figure 2F). These experiments mechanistically linked pyruvate transport to metabolic homeostasis that limits iTreg inflammatory response. We then explored whether extracellular cues could trigger metabolic alterations and inflammatory responses by altering mitochondria-ER ultrastructure.

IL-21 Stimulation of Human iTregs Promotes a Hypermetabolic State

IL-21 can enhance IFN-γ and IL-17 expression in LP T cells from human IBD subjects^{33, 34}, mirroring MPC inhibition. We then hypothesized that exposure of iTregs to IL-21 would induce metabolic alterations linked to inflammatory response. Indeed, Central Metabolism PCR Array and RT-qPCR demonstrated that IL-21 independently upregulated transcripts of rate-limiting enzymes associated with glycolysis and effector T cell response¹⁴ (Figure 3 and Supplementary Figure 3). These include SLC2A3 (GLUT3), hexokinase 2 (HK2), glucose phosphate isomerase (GPI), enolase 1/2 (ENO1/2), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), PKM2, monocarboxylate transporter 4 (MCT4, also known as SLC16A3), and hypoxia-inducible factor 1 alpha (HIF1A) (Figure 3A–C, 3F). IL-21 also amplified the citrate-to-acetyl-CoA shuttle system previously associated with glycolytic-lipogenic metabolism in Th17 cells³⁵. These include citrate synthase (CS), citrate transporter (SLC25A1), ATP citrate lyase (ACYL), acetyl-CoA carboxylase 1 (ACC1; ACACA), and fatty acid synthase (FASN) (Figure 3A, D, E). IL-21 transcriptionally activated fatty acid oxidation (FAO) and glutaminolysis that are known to support the TCA cycle, OXPHOS, and anabolic demands (Figure 3A, B), including glutamate oxaloacetate transaminase 1 (GOT1) previously linked to 2-hydroxyglutarate (2-HG) generation and Th17 cell commitment³⁶. IL-21 did not have a significant effect on FOXP3 and TGFB1 mRNA (Figure 3F, 3G). In summary, profiling of IL-21-stimulated iTregs suggests a metabolic rewiring to glycolysis and other compensatory pathways (Figure 3H). IL-21-induced metabolism was associated with inflammatory response, as evidenced by elevated IFNG, IL17A, and IL17F (P < 0.05, Figure 3I) while there was no reduction in the percentage of cells expressing FOXP3 and other markers (Figure 3J).

Figure 3. IL-21 Stimulation of Human iTregs Promotes a Hypermetabolic State.

(A–I) Transcriptional profiling of human iTregs ± IL-21 (100 ng/ml) in serum-free media in the absence of TCR and CD28 activation.

(A) Left, experimental workflow for the metabolic transcriptional profiling of iTregs. Right, heatmap of 43 metabolic transcripts (IL-21/vehicle, p < 0.05) and the associated metabolic processes (n = 3).

(B) Volcano plot illustrates all detected 211 metabolic genes (IL-21/vehicle, n = 3). Red dots denote genes with >1.5-fold change and p-value of <0.05 while blue dots denote <−1.0-fold change and p-value of <0.05.

(C–G) Relative mRNA expression via RT-qPCR in iTregs ± IL-21 (n = 4). Expression of metabolic genes

(C–E), transcription factors (F), and anti-inflammatory cytokines (G); Mann-Whitney U test.

(H) Schematic illustrates metabolic genes (shown in blue) upregulated in IL-21-stimulated iTregs.

(I) Relative mRNA of inflammatory genes in iTregs via RT-qPCR ± IL-21 (n = 4); Mann-Whitney U test.

(J) Percentage of iTregs positive for FOXP3 and surface markers, as determined by FACS (n = 3–9).

Data represents mean ± SEM. * p < 0.05 and *** p < 0.001, using a two-tailed Student’s t-test. NS (not significant).

IL-21 Dissociates Mitochondria from ER, Resulting in Pyruvate Imbalance and Sensitization to IL-12-induced Inflammatory Response

Addressing a mechanism by which IL-21 induced these transcriptional changes, we found that Tregs exposed to IL-21 (2 h) displayed reduced mitochondria-ER appositions, with altered mitochondrial morphology and volume, as determined by PLA, TEM, live-cell imaging, and serial block-face scanning EM (SEM) (Figure 4A–C and Supplementary Figure 4A, B). Glucose-regulated protein 75 (GRP75) tethers VDAC1 to IP3R1^{12, 37}, and in agreement, IL-21 reduced GRP75 co-localization with mitochondria (Supplementary Figure 4C). Unlike IL-21, other control cytokines IL-6, IL-23, and IL-12 failed to disrupt mitochondria-ER interaction within the time point evaluated (Figure 4A, Supplementary Figure 4D), indicating IL-21 as a potential negative regulator of mitochondria-ER coupling. Mitochondria-ER interaction is functionally coupled to GSK3β inactivation (via phosphorylation), and subsequent VDAC1 activation and pyruvate entry into mitochondria^{12, 31, 38}. We found that IL-21 reduced phosphorylated GSK3β (pSer9-GSK3β), the inactive form (P < 0.01 by immunoblot, P < 0.05 by FACS, Figure 4D and Supplementary Figure 4E). We and others interpret this loss of inactive form as a gain in GSK3β enzymatic activity, given the unspecific nature of antibodies raised against GSK3β active moiety. Increased pTyr705-STAT3 indicated cellular responsiveness to cytokines (Figure 4D), and IL-21 did not impact the β-catenin pathway (Supplementary Figure 4E bottom). We then speculated that IL-21-induced mitochondria-ER defect would decrease intracellular ATP, due to impaired mitochondrial pyruvate metabolism, and indeed, ATP was expectedly reduced (P < 0.05, Figure 4E). Thus, our data suggest that IL-21 uncouples mitochondria from ER, resulting in GSK3β activation and disruption of ATP production.

Figure 4. IL-21 Dissociates Mitochondria from ER, Resulting in Pyruvate Imbalance and Sensitization to IL-12-induced Inflammatory Response.

(A) Representative PLA images of mito-ER contact in iTregs ± 50 ng/ml of IL-6 (n = 113 cells), IL-23 (n = 131 cells), or IL-21 (n = 221 cells) vs. vehicle (n = 115 cells); scale bar, 2 μm. Graph shows mito-ER contact (red PLA signals) per cell (n = 2 independent experiments).

(B) Representative TEM images of iTregs ± IL-21, with black arrows indicating electron-dense regions; scale bar, 2 μm. Graphs show quantitation of mito-ER contact (n = 19 vs. n = 16 cells) (left), aspect ratio per mitochondrion (n = 167 vs. n = 101 mitochondria) (middle), and mitochondrial aspect ratio per cell (n = 19 vs. n = 16 cells) (right).

(C) Representative PLA images show mito-ER contact in human nTregs treated with vehicle or IL-21 after activation and TGF-β1 stimulation for 24 h; scale bar, 5 μm (n = 2 independent experiments).

(D) Representative immunoblots from iTregs ± cytokines (100 ng/ml). The red asterisk shows a reduction in GSK3β inactive form (top) (n = 3). Bar graphs show pSer9-GSK3β levels by immunoblot (n = 3) and the percentage of pSer9-GSK3β-expressing cells by FACS (n = 4).

(E) Intracellular ATP levels in iTregs ± IL-21 (50 ng/ml) (n = 5); Mann-Whitney U test.

(F and G) Extra- and intra-cellular lactate and pyruvate abundance in iTregs cultured in normal conditions ± IL-21 (100 ng/ml), LY2090314 GSK3 inhibitor (0.025 μM), or both (n = 3).

Data represents mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001, using two-tailed Student’s t-test or one-way ANOVA followed by Bonferroni test for multiple comparisons.

To understand how GSK3β enzymatic activity is linked to IL-21-induced nutrient metabolism, we quantified the abundance of metabolites under standard culturing conditions. Extracellular pyruvate and lactate were more abundant in the media collected from IL-21-stimulated iTregs (6–18 h) than in vehicle-treated cells (Figure 4F); however, excreted glutamine-derived glutamate was less abundant at the 6 h early time point (Supplementary Figure 4F). IL-21 increased intracellular lactate and pyruvate levels (Figure 4G) as well as glycolysis intermediates and TCA cycle metabolites (Supplementary Figure 4G), which is consistent with data in Figure 3A. In summary, IL-21-induced mitochondria-ER defect is associated with dysregulation of extra- and intra-cellular lactate and pyruvate.

To mechanistically link GSK3β activity and pyruvate-lactate imbalance to inflammatory cytokine expression, we hypothesized that pharmacologic inhibition of active GSK3β would restore metabolite levels and consequently suppress inflammatory cytokine expression. Consistent with our hypothesis, treatment with a pharmacologic inhibitor of GSK3α and GSK3β isoforms (LY2090314)³⁹, herein referred to as LY (0.025–0.1 μM), reversed IL-21-induced metabolite imbalance, including lactate and pyruvate levels (Figure 4F, G, and Supplementary Figure 4F, G). We then examined the anti-inflammatory effect of LY2090314 in the same experimental context as our VDAC1 and MPC inhibition studies by utilizing iTregs exposed to IL-21 and IL-12 as our model system, given that IL-21 also sensitized cells to IL-12-induced IFN-γ production (Supplementary Figure 4H). LY2090314 and the inhibitor of the rate-limiting step in glycolysis (2-deoxy-d-glucose, 2-DG, 10 μM, Supplementary Figure 4I) reduced the percentage of IFN-γ⁺ and TNF-α⁺ iTregs (Supplementary Figure 4J), which is consistent with Figure 3A and 4F, G. Using established pharmacological inhibitors¹⁴, we examined the contribution of other impacted metabolic pathways to inflammatory cytokine production (Supplementary Figure 4I). ETC complex I and III inhibitors (rotenone and antimycin A, respectively) and ATP uncoupler (FCCP) diminished the percentage of IFN-γ⁺ and or TNF-α⁺ iTregs to various extents (Supplementary Figure 4J), which is consistent with the emerging role of mitochondria in mediating T cell effector response⁴⁰. On the contrary, PKM2 activator (TEPP-46) and FAO, ACYL, ACC1, TCA cycle enzyme, ETC complex II and V inhibitors had no significant effect on the percentage of IFN-γ⁺ and TNF-α⁺ iTregs (Supplementary Figure 4J, K). Collectively, IL-21 disrupts mitochondria-ER interaction and potentiates GSK3β function, resulting in metabolic alterations that promote IL-12-induced IFN-γ and TNF-α.

Methyl Pyruvate Supplementation Mirrors LY2090314 Treatment and Suppresses the Metabolic Basis of Inflammatory iTregs

We then comprehensively measured changes in OCR and ECAR (extracellular acidification rate due to lactate production, i.e., rate of glycolysis) to mechanistically investigate metabolic adaptations occurring in real-time in response to IL-21 stimulation (1–48 h). As verified in glucose concentrations (1–10 mM), IL-21 (1 h) reduced OCR (Figure 5A, B), coinciding with mitochondria-ER decoupling and GSK3β activation (Figure 3A–D). Consistent with data in Figure 3A, carnitine palmitoyltransferase 1A (CPT1A)-mediated initiation of long-chain FAO potentially contributed to IL-21-induced OCR (3–18 h) (Figure 5C, D), as CPT1A inhibitor, etomoxir (ETO, 50 μM, 3 h), restored OCR (Figure 5D). Thus, IL-21 induces OCR fluctuations, mirroring Th17 cells in which OXPHOS supports IL-17 production^{41, 42}.

Figure 5. Methyl Pyruvate Supplementation Mirrors LY2090314 Treatment and Suppresses the Metabolic Basis of Inflammatory iTregs.

(A) Representative OCR profile of iTregs in 1 mM glucose ± IL-21 (100 ng/ml) (n = 3). Bar graphs show calculated basal respiration and ATP production; mean ± SEM from 10 technical replicates.

(B) Representative OCR profile of iTregs in 10 mM glucose ± IL-21 (100–400 ng/ml) (n = 3). Bar graphs show calculated basal respiration, ATP production, maximal respiration, and spare respiratory capacity; mean ± SEM from 10–24 technical replicates.

(C) Representative OCR profile of iTregs ± IL-21 (100 ng/ml) in the presence of TCR and CD28 activation (n = 3). Bar graphs show calculated basal respiration, maximal respiration, ATP production, and spare respiratory capacity; mean ± SEM from 10 technical replicates.

(D) Representative OCR profile of iTregs ± IL-21 (100 ng/ml), etomoxir (ETO, 50 μM), or both (n = 3). Bar graphs show calculated basal respiration, maximal respiration, ATP production, and spare respiratory capacity; mean ± SEM from 5 technical replicates.

(E) Representative ECAR (top) and OCR (bottom) profiles of iTregs ± IL-21, LY2090314, or both (n = 3). Bar graphs show calculated glycolysis, glycolytic capacity, and glycolytic reserve (top) and maximal respiration and spare respiratory capacity (bottom); mean ± SEM from 10–12 technical replicates.

(F) Representative ECAR profile of IL-21 and IL-12-stimulated iTregs ± methyl pyruvate (MePyr, 10 mM) (n = 3). Graphs show calculated glycolysis and glycolytic capacity; mean ± SEM from 10–12 technical replicates.

(G) Graph shows percentage of IL-21 and IL-12-induced FOXP3⁺ IFN-γ⁺ iTregs ± LY2090314 or MePyr (n = 4).

(H) The schematic diagram illustrates IL-21-mediated metabolite imbalance in iTregs. Diagram was created with biorender.com

Data represents mean ± SEM. * p < 0.05., *** p < 0.001 and **** p < 0.0001, using two-tailed Student’s t-test or one-way ANOVA followed by Bonferroni test for multiple comparisons.

Notably, LY2090314 reversed ECAR and OCR induced by IL-21 (Figure 5E). Consistent with data in Figure 4J, mass cytometry by Time of Flight (CyTOF) showed that LY2090314 reduced IL-21 and IL-12-induced IFN-γ, TNF-α, and IL-17A across CD49D subpopulations (Supplementary Figure 5A, B). LY2090314 also reversed ECAR and or OCR induced by IL-6, IL-23, and UK5099 (Supplementary Figure 5C, D). These notable findings suggest that several proinflammatory cytokines can induce glycolysis, potentially via distinct mechanisms. Furthermore, GSK3β, by shuttling between its active and inactive forms, may act as a central metabolic checkpoint, which in turn dictates pyruvate localization (cytosolic vs. mitochondria) as supported by evidence from other cell types^{12, 31}.

Collectively, these mechanistic observations led us to hypothesize that circumventing mitochondria-ER defect or requirement by merely supplementing IL-21 and IL-12-stimulated Tregs with membrane-permeable MePyr would reduce ECAR and inflammatory response, mirroring GSK3β inhibition. Indeed, MePyr diminished ECAR of IL-21 and IL-12-stimulated iTregs (basal glycolysis, glycolytic capacity: P < 0.0001, Figure 5F), and it reduced the percentage of IFN-γ⁺ iTregs, mirroring LY2090314 treatment (P < 0.05, Figure 5G). Overall, our work suggests that enforced mitochondrial pyruvate entry via MePyr supplementation or LY2093014 treatment suppresses the metabolic phenotype of inflammatory iTregs (Figure 5H), resulting in reduced inflammatory response. Next, we examined the immune-suppressive capacity of IL-21R-deficient (Il21r^−/−) Tregs in alleviating murine colitis in comparison to wild-type (WT) Tregs.

IL-21-induced Metabolic Genes are Enriched in Refractory Human IBD, and IL-21R-deficient Tregs Effectively Lessen CD4⁺ T Cell-induced Colitis in Mice

We first examined whether IL-21-induced metabolic genes enriched in our in vitro iTregs (Figure 3A) were represented in Tregs from severe lesions of human IBD. We analyzed single-cell RNA-sequencing (scRNA-seq) dataset from human CD ileal lesions (Martin et. al), in which a pathogenic cell-cell landscape consisting of IgG plasma cells, inflammatory mononuclear phagocytes, activated T cells, and stromal cells (termed GIMATS^high module) predicts patient resistance to anti-TNF therapy¹⁸. Notably, in Treg clusters from inflamed tissues of GIMATS^high patients, we found higher expression of genes associated with glycolysis (GAPDH, ENO1, ALDOA, LDHB, and TPI1), nucleotide metabolism (CMPK1, GUK1, and APRT), FAO (PAFAH1B3), and glutaminolysis (glutamine transporter SLC38A1) than that of GIMATS^low patients (Figure 6A). Furthermore, some of these metabolic genes were also upregulated in Treg clusters from inflamed CD tissues than that of adjacent uninflamed tissues from the same patients (Figure 6B). In summary, IL-21-induced metabolic genes, such as GAPDH, in our iTregs are enriched in intestinal Tregs derived from refractory IBD patients. The expression of inflammatory cytokines in glycolytic immune cells has been reported to rely on GAPDH¹⁴. Like the MePyr control, GAPDH enzymatic inhibition with dimethyl fumarate (DMF, 25–100 μM) and heptelidic acid (HA, 0.05 μM) reduced the percentage of IL-21 and IL-12-induced IFN-γ⁺ iTregs (Supplementary Figure 6A, B). Furthermore, IL-21 and IL-12 stimulation of iTregs increased GAPDH enzyme activity, and this outcome was reversed by MePyr, 2-DG, and LY2090314 (Supplementary Figure 6C). This suggests that IL-21 and IL-12-induced glycolysis linked to IFN-γ production in iTregs involves enhanced GAPDH function in a manner reversible by MePyr.

Figure 6. IL-21-induced Metabolic Genes are Enriched in Refractory Human IBD, and IL-21R-deficient Tregs Effectively Lessen CD4⁺ T Cell-induced Colitis in Mice.

(A) Violin plots show the log2 normalized UMI of metabolic genes in human Treg clusters from Crohn’s disease (CD) inflamed tissues of GIMATS (IgG plasma cells, inflammatory MNP, and activated T and stromal cells) module (Wilcoxon test; P); n = 5 for GIMATS^high patients and n = 4 for GIMATS^low patients.

(B) Violin plots show the log2 normalized UMI of metabolic genes in human Treg clusters from CD inflamed vs. adjacent non-inflamed tissues from the same patients (n = 9 patients) (Wilcoxon test; P).

(C) The schematic diagram illustrates colitis induction with pathogenic T cells and rescue approach with adoptive Treg transfer. Change in body weight of mice during CD4⁺ T cell-induced colitis rescue (n = 5–7 mice per group).

(D) DAI and MCHI of colitis mice on week 7. MCHI was assessed by a blinded pathologist.

(E) Hematoxylin and eosin (H&E) staining of colon sections of colitis mice on week 7; scale bar, 50 μm.

(F) Serum cytokine levels in colitis mice on week 7.

(G) Serum cytokine levels in colitis mice on week 11.

(H) DAI and MCHI of colitis mice as well as H&E staining of colon sections on week 11.

(I) Experimental workflow and dot plot of sorted splenic CD4⁺ CD25⁺ T cells (Tregs) from colitis mice.

(J) Representative images of mito-ER contact in splenic ex vivo Tregs; scale bar, 2 μm. Graph shows the average number of mito-ER contact per mouse or cell.

(K) Suppression of CD4⁺ CD25⁻⁻ T cell proliferation in vitro by Tregs.

Data represents mean ± SEM. * p < 0.05, ** p < 0.01, and **** p < 0.0001, using two-way ANOVA followed by Tukey for multiple comparisons (C), non-parametric Kruskal-Wallis test followed by Dunn’s multiple comparisons (vehicle vs. Tregs) and two-tailed Student’s t-test (WT vs. il21r^−/− Tregs) (D, H), multiple unpaired t tests (F, G), two-tailed Student’s t-test (J), using one-way ANOVA followed by Tukey for multiple comparisons (K)

Next, we hypothesized that Il21r^−/− Tregs would resolve colitis more efficiently than WT Tregs. We adoptively transferred naïve CD4⁺ CD45RB^high T cells into recombinase activating gene-1 (Rag1)^−/− mice to induce colitis, followed by injection with vehicle or Tregs (WT versus Il21r^−/− Tregs) on day 0 to prevent disease or on week 3 with varied numbers of cells to rescue disease. Colitis mice injected with vehicle expectedly lost their body weight, displayed increased disease activity index (DAI), and developed colitis based on blinded histology assessment (mouse colitis histology index (MCHI) scoring). In the colitis prevention approach, although both WT and Il21r^−/− Tregs improved weight gain (Supplementary Figure 6D) and reduced DAI (Supplementary Figure 6E), WT Tregs failed to efficiently restrain tissue inflammation and damage (MCHI, P > 0.05, Supplementary Figure 6F) as well as serum IL-6 com (P > 0.05, Supplementary Figure 6G). In the colitis rescue approach, Il21r^−/− Tregs (250,000) successfully stabilized mice weight (P < 0.05, Figure 6C), reduced DAI, MCHI (P < 0.05, Figure 6D, E), and serum TNF-α (P < 0.001) compared to the same number of WT Tregs (Figure 6F). Consistently, this enhanced colitis-suppressive effect was replicated by a lower number of Il21r^−/− Tregs (100,000) in comparison to WT Tregs, as evidenced by increased weight gain (Supplementary Figure 6H, I) and decreased serum TNF-α, IFN-γ as well as reduction in MCHI (Figure 6G, H). Taken together, using these complementary approaches, IL-21R-deficient Tregs exhibit enhanced capacity in suppressing colitis induced by pathogenic CD4⁺ T cells compared to WT Tregs. To link the improved functionality of Il21r^−/− Tregs to mitochondria-ER function, we assayed for mitochondria-ER appositions in CD4⁺ CD25⁺ T cells (FOXP3⁺ Tregs) sorted from spleens and intestinal lamina propria of treated colitis mice, as confirmed in Supplementary Figure 6H, and expectedly found that ex vivo Il21r^−/− Tregs displayed increased VDAC1-IP3R1 binding compared to ex vivo WT Tregs (Figure 6I, J and Supplementary Figure 6J). Moreover, the in vitro suppressive function of Il21r^−/− Tregs was reversed by VDAC1 inhibition with clotrimazole pre-treatment (Figure 6K), thus supporting the potential role of mitochondria-ER function in maintaining Treg phenotype and immunosuppressive function.

Discussion

Although intestinal Tregs expressing inflammatory cytokines in CD and UC patients have been described^16–18, the mechanism responsible for this inflammatory phenotype and its contribution to disease are poorly understood. Our prominent findings include the identification of mitochondria-ER appositions in human Tregs, which we believe facilitate pyruvate transport and its metabolism in the mitochondria. Impairing mitochondrial pyruvate entry by targeting mitochondria-ER architecture induces metabolic dysfunction and renders iTregs susceptible to acquiring an effector T cell-like phenotype. IL-21 uniquely perturbs mitochondria-ER ultrastructure and exploits GSK3β to promote Treg metabolism that favors inflammatory immune response. GSK3β inhibition or MePyr supplementation potentially bypasses mitochondria-ER requirement to suppress iTreg inflammatory response and its metabolic basis. Perturbations to mitochondria-associated membranes and the resulting regulatory immune cell defects could therefore be a generalizable mechanism pertinent to other chronic inflammatory conditions and gut pathophysiology, such as celiac disease characterized by elevated serum IL-21 and gluten-specific CD4⁺ T cells secreting IL-21 in the blood and lamina propria. Our study indicates that GSK3β is perhaps constitutively active – acting as a central metabolic checkpoint at the pyruvate bifurcation point – given that its pharmacologic inhibition affected basal TNF-α, ECAR, and OCR in normal iTregs. Adoptive transfer of IL-21R-deficient Tregs more efficiently ameliorates disease onset and progression, which mechanistically supports the relevance of IL-21-IL-21R axis in vivo. Overall, our study suggests that the ability of pathogenic cues to instigate metabolic alterations that result in Treg dysfunction might induce resistance to current monotherapies.

We showed that TGF-β1 and IL-21 had opposing effects on mitochondria-ER interaction. We suspect this may involve the re-organization of actin and microtubule networks, with subsequent changes to the subcellular localization of chaperones such as GRP75. IL-21 stimulation activated several metabolic pathways, including pathways supportive of OXPHOS. Although mitochondrial metabolism is important for Treg function under steady-state conditions⁴³, mtROS and consequent DNA damage have been linked to Treg cell death and autoimmune pathogenesis⁴⁴. However, in our study, IL-21-induced mitochondrial alterations were associated with IFN-γ and TNF-α production. Presumably, diseasespecific microenvironmental factors control metabolic rewiring and Treg cell fate decisions (inflammatory vs. cell death). Along this line, mitochondrial abnormality in intestinal epithelial cells has been associated with IBD⁴⁵. Our study raises the possibility that IL-21 may broadly instigate mitochondrial dysfunction in multiple cell types, leading to metabolic alterations culminating in chronic inflammation.

We found that the prototypical glycolysis inhibitor (2-DG) significantly decreased IL-21 and IL-12-induced IFN-γ and TNF-α production by iTregs; however, the precise glycolytic mechanisms are not understood. It might involve proteins, such as HIF1α, GAPDH, mechanistic target of rapamycin, GLUTs, and MCTs previously linked to effector T cell function⁴. Furthermore, the contribution of metabolic pathways, such as one carbon and nucleotide metabolism, to Treg biology warrants to be investigated. Paradoxically, we found an upward trend in IL-10 expression in iTregs in response to IL-21 and IL-12, perhaps due to enhanced cholesterol biosynthesis previously linked to IL-10 induction⁴⁶. Of note, our inflammatory iTreg in vitro model mirrors data from inflamed tissues of UC patients in which FOXP3⁺ IL10⁺ T cells were also the primary source of TNF-α¹⁷. We speculate that IL-21-induced IL-10 is an attempt to dampen IL-17 expression, given that IL-10 signaling can suppress IL-17 expression. Thus, our inflammatory iTregs in vitro resemble FOXP3⁺ T cells reported in IBD patients^{17, 18}. Elucidating how IL-21-induced inflammatory cytokines act in an autocrine manner to further compromise Treg function might reveal mechanisms pertinent to IBD. IL-21 reduced CD49D (α4), nevertheless, CD49D^high iTregs maintained TNF-α expression, consistent with the notion that highly inflammatory T cells possess gut-infiltrating capability. IL-21 may regulate Treg trafficking, with implications in intestinal tissue damage and extraintestinal manifestations; however, experiments are needed to substantiate this speculation. Interestingly, a higher percentage of α4β7^low Tregs was observed in CD patients¹⁵, and the restoration of α4β7 in expanded ex vivo Tregs is being explored for autologous transplant to treat CD patients (NCT03185000). This implies that human Tregs, supported by evidence in murine models, also require α4β7 for selective homing to the gut for immunosuppressive function.

Overall, our studies uncovered a link between IL-21 and mitochondria-ER dysfunction, which results in enhanced GSK3β function, hypermetabolic state, and iTreg inflammatory response. We also provided several therapeutic strategies for halting Treg’s inflammatory state. Repurposing GSK3 inhibitor (LY2090314) for pharmacological intervention or generation of autologous Tregs might be beneficial. Remarkably, LY2090314 was well tolerated in a Phase 2 study for cancer treatment³⁹. Our findings provide the basis for future characterization of inflammatory Tregs that may inspire the development of immunomodulatory therapies.

Key Resources Table

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies
Anti-human/mouse/rat VDAC1 (Lot #3507477001)	ORIGENE	Cat#TA326858
Anti-human/mouse/rat/monkey GRP75	Abcam	Cat#ab2799
Anti-human/mouse/rat/monkey TOM20	Cell Signaling	Cat#42406S
Anti-human/mouse/rat IP3R-I	Santa Cruz	Cat#sc-271197
Anti-human/mouse/rat phospho β-catenin-Serine 37	PetroTech	Cat#28776-1-AP
Anti-human/mouse/rat phospho β-catenin-Serine 33	PetroTech	Cat#80067-1-RR
Anti-human/mouse/rat β-catenin	PetroTech	Cat#66379-1-Ig
Alexa Fluor 488 Anti-human FOXP3 (clone 259D)	BioLegend	Cat#320212
Alexa Fluor 488 Anti-human CD25 (clone BC96)	BioLegend	Cat#302616
PE anti-human CD39 (clone A1)	BioLegend	Cat#328208
PerCP/Cy5.5 anti-human CD152 (CTLA4) (clone BNI3)	BioLegend	Cat#369608
Anti-human/mouse/rat/monkey phospho-Serine 9 GSK3β (D85E12)	Cell Signaling	Cat#5558S
Anti-human/mouse/rat/monkey GSK3β (27C10)	Cell Signaling	Cat#9315
Anti-human/mouse/rat/monkey β-actin (8H10D10)	Cell Signaling	Cat#3700S
Anti-human/mouse/rat/monkey STAT3 (124H6)	Cell Signaling	Cat#9139S
Anti-human/mouse/rat HK-I	Invitrogen	Cat#MA5-15680
APC anti-human CD49D (α4) (clone 9F10)	BioLegend	Cat#304308
PE anti-human CD103 (integrin αE) (clone Ber-ACT8)	BioLegend	Cat#350206
APC/Cyanine7 anti-human IFN-γ (4S.B3)	BioLegend	Cat#502530
PE anti-human TNF-α (MAb11)	BioLegend	Cat#502909
Alexa Fluor 488 anti-human CD4 (clone RPA-T4)	BioLegend	Cat#300519
PE anti-mouse CD45RB (clone c363-16A)	BioLegend	Cat#103308
Alexa Fluor 488 CD25 (clone PC61)	BioLegend	Cat#102017
Alexa Fluor 647 anti-human phospho-Serine 9 GSK3β	R&D SYSTEMS	Cat# IC25062R
Alexa Fluor 488 Mouse IgG1, k (clone MOPC-21)	BioLegend	Cat#400134
APC Mouse IgG1, k (clone MOPC-21)	BioLegend	Cat#400119
PE Mouse IgG1, k (clone MOPC-21)	BioLegend	Cat#400114
APC/Cyanine 7 Mouse IgG1, k (clone MOPC-21)	BioLegend	Cat#400128
Brilliant Violet 421 Mouse IgG1, k (clone MOPC-21)	BioLegend	Cat#400157
PE/Cy7 Mouse IgG1, k (clone MOPC-21)	BioLegend	Cat#400125
PercP/Cy5.5 Mouse IgG1, k (clone MOPC-21)	BioLegend	Cat#400150
Human TruStain FcX™	BioLegend	Cat#422302
CellTak	Corning	Cat#354242
Chemicals, Peptides, and Recombinant Proteins
LY2090314	Selleckchem	Cat#S7063
TCS 2002	TOCRIS	Cat#3869
Methyl Pyruvate	Sigma-Aldrich	Cat#371173
MOXTM Regent	Thermo Fisher Scientific	Cat#TS-45950
MSTFA+1% TMCS	Thermo Fisher Scientific	Cat#TS-48915
Methanol CHROMASOLV®, for HPLC	Sigma-Aldrich	Cat#34860
Water for HPLC	Sigma-Aldrich	Cat#270733
TSP-d4	Sigma-Aldrich	Cat#269913
MitoTracker RedCMXRos	Thermo Fisher Scientific	Cat#M7512
ER-Tracker™ Blue-White DPX	Thermo Fisher Scientific	Cat#E12353
Oligomycin	Abcam	Cat#ab141829
FCCP	Abcam	Cat#ab120081
Rotenone	Abcam	Cat#ab143135
Antimycin A	Abcam	Cat#ab141904
2-deoxyglucose (2-DG)	APEXBIO	Cat#B1027
Seahorse XF 1.0 M Glucose solution	Agilent Technologies	Cat#103577-100
Seahorse XF 200 mM Glutamine solution	Agilent Technologies	Cat#103579-100
Seahorse XF 100 mM Pyruvate solution	Agilent Technologies	Cat#103578-100
XF RPMI Medium	Agilent Technologies	Cat#103576-100
Purified NA/LE Mouse Anti-human CD3	BD Pharmingen	Cat#555329
Purified NA/LE Mouse Anti-human CD28	BD Pharmingen	Cat#555725
Recombinant human IL-2	PetroTech	Cat#200-02
Recombinant human TGF-β1	PetroTech	Cat#100-21C
Recombinant human IL-12 p70	PetroTech	Cat#200-12
Recombinant human IL-1β	PetroTech	Cat#200-01B
Recombinant human IL-6	PetroTech	Cat#200-06
Recombinant human IL-21	PetroTech	Cat#200-21
Recombinant human IL-23	PetroTech	Cat#200-23
Recombinant human IL-4	PetroTech	Cat#200-04
Purified anti-human IFN-γ (clone B27)	BioLegend	Cat#506502
Purified anti-human IL-4 (clone 8D4-8)	BioLegend	Cat#500702
Clotrimazole	TOCRIS	Cat#4096
Bifonazole	Sigma-Aldrich	Cat#B3563
UK5099	EMD Millipore	Cat#5.04817.0001
TEPP-46 (ML265, CID-44246499, NCGC001186528)	Selleckchem	Cat#S7302
BMS-303141	Sigma-Aldrich	Cat#SML0784
Calyculin A	Abcam	Cat#141784
Heptelidic acid (HA)	Abcam	Cat#ab144269
Dimethyl fumarate (DMF)	Sigma-Aldrich	Cat#S2596
Cpd9, ACC1 inhibitor	EMD Millipore	Cat#5.34335.0001
2-Thenoyltrifluoroacetone (TTFA)	Sigma-Aldrich	Cat#T27006
Sodium Fluoroacetate	MP, Biochemicals, LLC	Cat#201080
Etomoxir sodium salt hydrate	Sigma-Aldrich	Cat#E1905
Fibronectin Human, Natural	Corning	Cat#354008
MitoTracker Green	Thermo Fisher Scientific	Cat#M7514
NE-PER™ Nuclear and Cytoplasmic Extraction Reagents	Thermo Fisher Scientific	REF#78833
Cell Trace Violet Cell Proliferation Kit	Thermo Fisher Scientific	Cat#C34751
Purified NA/LE Hamster Anti-mouse CD3e (clone145-2C11)	BD Pharmingen	Cat#553057
Purified NA/LE Hamster Anti-mouse CD328 (clone145-2C11)	BD Pharmingen	Cat#553294
Recombinant mouse IL-12 p70	PetroTech	Cat#210-12
Recombinant mouse IL-1β	PetroTech	Cat#211-11B
Recombinant mouse IL-6	PetroTech	Cat#210-16
Recombinant mouse IL-21	PetroTech	Cat#210-21
Recombinant mouse IL-23 p40	R&D SYSTEMS	Cat#1887-ML-010
LEAF™ Purified anti-mouse IFN-γ (clone XMG1.2)	BioLegend	Cat#505812
Purified anti-mouse IL-4 (clone 11B11)	BioLegend	Cat#504102
Mouse Dynabeads CD3/CD28	Gibco	Cat#11452D
Biological samples and Experimental Models
Healthy adult – peripheral blood mononuclear cells (males)	Mayo Clinic	N/A
Healthy adult – intestinal biopsies (male)	Mayo Clinic	N/A
C57BL/6J mice (males)	The Jackson Laboratory	Stock no:000664
C57BL/6J Rag1−/− mice (males)	The Jackson Laboratory	Stock no: 002216
C57BL/6NJ wildtype (one male and one female)	The Jackson Laboratory	Stock no: 005304
Total body Il21r−/− (one male and one female)	The Jackson Laboratory	Stock no: 019115
Software and Algorithms
FlowJo version10.2	FlowJo, LLC	https://www.flowjo.com
Zen 3.0 (blue edition)	Zen	https://www.zeiss.com
Bio-Rad Image Lab	Bio-Rad	https://www.bio-rad.com
GraphPadPrism 8	GraphPad software	https://www.graphpad.com
Seahorse Bioscience Wave Desktop	Agilent Technologies	https://www.agilent.com
ImageJ	NIH	https://imagej.nih.gov
Photoshop Adobe	Adobe	https://www.adobe.com
Critical Commercial Assays
BD™ Cytometric Bead Array (CBA) Mouse Th1/Th2/Th17 Cytokine Kit	BD Biosciences	Cat#560485
ENLITEN ATP Assay System	Promega	Cat#FF2000
GAPDH Activity Assay Kit (Colorimetric)	Abcam	Cat #ab204732
Human Treg Phenotyping Panel Kit	Fluidigm	Cat#201060
RNeasy Plus Mini Kit	QIAGEN	Cat#74134
Seahorse XF24 Flux/Pak	Agilent Technologies	Cat#100850-001
Seahorse XFe96 Flux/Pak	Agilent Technologies	Cat#102416-100
Arraystar SYBR Green qPCR Mater Mix	ARRAYSTAR INC	Cat#AS-MR-006-5
NuRNA™ Human Central Metabolism PCR Array (Roche Light Cycler 480)	ARRAYSTARINC	Cat#AS-NM-004-1-R
Spike-in RNA	ARRAYSTARINC	Cat#AS-SP-001-1
Duolink™ In Situ PLA Anti-Mouse PLUS	Sigma-Aldrich	Cat#DUO92001
Duolink™ In Situ PLA Anti-Rabbit MINUS	Sigma-Aldrich	Cat#DUO92005
Duolink™ In Situ Detection Reagents Red	Sigma-Aldrich	Cat#DUO92008
CD4+ T cell isolation kit, mouse	Miltenyi Biotec	Cat#130-104-454
CD4+ CD62L+ (naive) T cell isolation kit, mouse	Miltenyi Biotec	Cat#130-106-643
CD4+ CD25+ (Treg) T cell isolation kit, mouse	Miltenyi Biotec	Cat#130-091-041
CD4+ T cell isolation kit, human	Miltenyi Biotec	Cat#130-096-533
Accell Human VDAC1 siRNA SMARTPool	Dharmacon™	Cat ID: E-019764-00-0050
Accell Non-targeting Control Pool	Dharmacon™	Cat ID: D-001910-10-50
CD45RA+ (naive) cell isolation kit, human	Miltenyi Biotec	Cat#130-045-901
CD4+ CD127dim T cell isolation kit, human	Miltenyi Biotec	Cat#130-094-775
Others
RPMI Medium 1640 (1X) [+] L-Glutamine	Gibco	REF#11875-093

BACKGROUND AND CONTEXT

Mechanisms governing the metabolic basis of Tregs and their resulting immunosuppressive activity in the intestine are poorly defined. The role of interleukin 21 in instigating metabolic reprogramming and consequent incapacitation of Tregs is uncharacterized.

NEW FINDINGS

Interleukin 21 impairs mitochondrial pyruvate metabolism and promotes inflammatory response in Tregs by disrupting mitochondria-endoplasmic reticulum function and instigating glycogen synthase kinase 3β-driven metabolic program. Methyl pyruvate supplementation or pharmacologic inhibition of glycogen synthase kinase 3β restores Treg metabolic state and phenotype, and interleukin 21 receptor-deficient Tregs efficiently treat colitis.

LIMITATIONS

The contribution of other metabolic pathways activated by interleukin 21 to Treg biology needs further evaluation.

CLINICAL RESEARCH RELEVANCE

The metabolic transcriptional landscape of Tregs exposed to an inflammatory milieu is altered in vitro and in vivo, suggesting potential metabolic vulnerabilities. Our work provides proof-of-concept preclinical studies for generating highly immunosuppressive Tregs by improving cellular metabolic fitness to treat immune-mediated diseases, such as inflammatory bowel disease and celiac disease.

BASIC RESEARCH RELEVANCE

Tregs are preferentially enriched with mitochondria-endoplasmic reticulum appositions, which are required for pyruvate transport into the mitochondria to promote metabolic homeostasis. Inhibition of mitochondrial pyruvate transport or stimulation with interleukin 21 induces a hypermetabolic state with enhanced glycolysis, which contributes to inflammatory response, cellular defect, and poor resolution of chronic intestinal inflammation.

LAY SUMMARY

Interleukin 21 induces metabolic alterations and acquisition of an inflammatory-like phenotype by perturbing mitochondria-endoplasmic reticulum crosstalk, thereby diminishing the capacity of Tregs in suppressing inflammatory bowel disease.

Abbreviations

FOXP3

forkhead domain–containing protein 3

IMM

inner mitochondrial membrane

OMM

outer mitochondrial membrane

MAM

mitochondria-associated membranes

VDAC1

voltage-dependent anion channel 1

IP3R1

inositol triphosphate receptor 1

MPC

mitochondrial pyruvate carrier

Mito-ER

mitochondria-endoplasmic reticulum

EM

electron microscopy

MePyr

methyl pyruvate

GSK3β

glycogen synthase kinase 3 beta

2-DG

2-deoxy-d-glucose

GAPDH

glyceraldehyde 3-phosphate dehydrogenase

IBD

inflammatory bowel disease

CD

Crohn’s disease

UC

ulcerative colitis

IL

interleukin

IP

intraperitoneally

mRNA

messenger RNA

OXPHOS

oxidative phosphorylation

FCCP

carbonyl cyanide-p-trifluoromethoxy phenylhydrazone

FAO

fatty acid oxidation

TCA

tricarboxylic acid

ECAR

extracellular acidification rate

OCR

oxygen consumption rate

ETC

electron transport chain

PBMC

peripheral blood mononuclear cell

LP

lamina propria

PLA

proximity ligation assay

PBS

phosphate-buffered saline

RNA-seq

RNA sequencing

TCR

T cell receptor

CD3

cluster of differentiation 3

CD28

cluster of differentiation 28

CD49D

integrin alpha 4

GLUT3

glucose transporter 3

PKM2

pyruvate kinase M2 isoform

TGF-β1

transforming growth factor beta 1

Th

T helper

TNF-α

tumor necrosis factor alpha

IFN-γ

interferon gamma

iTreg

induced regulatory T cell

nTreg

natural regulatory T cell

WT

wild-type